Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis
Received Date: Aug 30, 2015 / Accepted Date: Sep 30, 2016 / Published Date: Oct 05, 2016
Abstract
Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Erythropoietin (EPO) is a cytokine required to maintain erythroid cells. Recombinant human EPO
(rHuEPO) was found to act also on immune cells. Beneficial effects of rHuEPO therapy have been demonstrated in several experimental autoimmune models.
We have tested the effect of rHuEPO on the course of experimental autoimmune MG (EAMG) when treatment was initiated either at the acute or at the chronic phase of the disease. A significant ameliorating effect on the course of EAMG was achieved when the treatment started at the acute phase of EAMG, which was accompanied by elevated numbers of Treg. In addition, rHuEPO reduced the levels of anti-acetylcholine receptor (AChR) antibodies.
Our findings suggest that rHuEPO interferes in the course and progression of EAMG and may thus open new clinical opportunities for its use for immunomodulation of MG.
Keywords: Erythropoietin; Myasthenia Gravis; Autoimmune disorders
Citation: Reuveni D, Gertel-Lapter S, Aricha R, Mittleman M, Fuchs S, et al. (2016) Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis. J Clin Exp Neuroimmunol 1:108.
Copyright: ©2016 Reuveni D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Open Access Journals
Article Usage
- Total views: 11317
- [From(publication date): 10-2016 - Apr 24, 2024]
- Breakdown by view type
- HTML page views: 10572
- PDF downloads: 745
